wow .. i would like to know that also ... my guess is that they have been stingy with increases while going through
this transition period .. once the newer drugs achieve their expected sales levels , cash flow should increase and
maybe then we'll get something more than token increases .. maybe next year ??? for the time being ,
i cannot complain , as the pps has been going gangbusters .. i came in @ 19 and added more @ 31 ...
still , getting that div up there will be very very nice ... garce
They announced several years ago their intention was to increase the dividend 4 cents per year for the next 5 yrs. I believe we're in year 3. In the meantime, we're being rewarded to have patience with some nice in PPS increases.
The current problem has been the slower than expected uptake with Eliquis. The mishandling of trial data has been a real killer giving the competition a chance to get a better foothold in the market place.
Unfortunately, BMS has never had a great relationship with the FDA and we're paying the price.